The DOI matches its Crossref record; 27 of the 29 references it cites were found in a registry or an index.
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Open accessAbstract
Background Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic lymphoma kinase (ALK) genetic aberrations (EGFR-/ALK-), but clinical benefit in patients with EGFR mutations or ALK rearrangements (EGFR+/ALK+) has not been shown. We assessed the effect of durvalumab (anti-PD-L1) treatment in three cohorts of patients with NSCLC defined by EGFR/ALK status and tumour expression of PD-L1.Methods ATLANTIC is a phase 2, open-label, single-arm trial at 139 study centres in Asia, Europe, and North America. Eligible patients had advanced NSCLC with disease progression following at least two previous systemic regimens, including platinum-based chemotherapy (and tyrosine kinase inhibitor therapy if indicated); were aged 18 years or older; had a WHO performance status score of 0 or 1; and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Key exclusion criteria included mixed small-cell lung cancer and NSCLC histology; previous exposure to any anti-PD-1 or anti-PD-L1 antibody; and any previous grade 3 or worse immune-related adverse event while receiving any immunotherapy agent. Patients in cohort 1 had EGFR+/ALK+ NSCLC with at least 25%, or less than 25%, of tumour cells with PD-L1 expression. Patients in cohorts 2 and 3 had EGFR-/ALK- NSCLC; cohort 2 included patients with at least 25%, or less than 25%, of tumour cells with PD-L1 expression, and cohort 3 included patients with at least 90% of tumour cells with PD-L1 expression. Patients received durvalumab (10 mg/kg) every 2 weeks, via intravenous infusion, for up to 12 months. Retreatment was allowed for patients who benefited but then progressed after completing 12 months. The primary endpoint was the proportion of patients with increased tumour expression of PD-L1 (defined as ≥25% of tumour cells in cohorts 1 and 2, and ≥90% of tumour cells in cohort 3) who achieved an objective response, assessed in patients who were evaluable for response per independent central review according to RECIST version 1.1. Safety was assessed in all patients who received at least one dose of durvalumab and for whom any post-dose data were available. The trial is ongoing, but is no longer open to accrual, and is registered with ClinicalTrials.gov, number NCT02087423.Findings Between Feb 25, 2014, and Dec 28, 2015, 444 patients were enrolled and received durvalumab: 111 in cohort 1, 265 in cohort 2, and 68 in cohort 3. Among patients with at least 25% of tumour cells expressing PD-L1 who were evaluable for objective response per independent central review, an objective response was achieved in 9 (12·2%, 95% CI 5·7-21·8) of 74 patients in cohort 1 and 24 (16·4%, 10·8-23·5) of 146 patients in cohort 2. In cohort 3, 21 (30·9%, 20·2-43·3) of 68 patients achieved an objective response. Grade 3 or 4 treatment-related adverse events occurred in 40 (9%) of 444 patients overall: six (5%) of 111 patients in cohort 1, 22 (8%) of 265 in cohort 2, and 12 (18%) of 68 in cohort 3. The most common treatment-related grade 3 or 4 adverse events were pneumonitis (four patients [1%]), elevated gamma-glutamyltransferase (four [1%]), diarrhoea (three [1%]), infusion-related reaction (three [1%]), elevated aspartate aminotransferase (two [<1%]), elevated transaminases (two [<1%]), vomiting (two [<1%]), and fatigue (two [<1%]). Treatment-related serious adverse events occurred in 27 (6%) of 444 patients overall: five (5%) of 111 patients in cohort 1, 14 (5%) of 265 in cohort 2, and eight (12%) of 68 in cohort 3. The most common serious adverse events overall were pneumonitis (five patients [1%]), fatigue (three [1%]), and infusion-related reaction (three [1%]). Immune-mediated events were manageable with standard treatment guidelines.Interpretation In patients with advanced and heavily pretreated NSCLC, the clinical activity and safety profile of durvalumab was consistent with that of other anti-PD-1 and anti-PD-L1 agents. Responses were recorded in all cohorts; the proportion of patients with EGFR-/ALK- NSCLC (cohorts 2 and 3) achieving a response was higher than the proportion with EGFR+/ALK+ NSCLC (cohort 1) achieving a response. The clinical activity of durvalumab in patients with EGFR+ NSCLC with ≥25% of tumour cells expressing PD-L1 was encouraging, and further investigation of durvalumab in patients with EGFR+/ALK+ NSCLC is warranted.Funding AstraZeneca.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar to EGFR-mutation, ALK rearrangement is also related to the poor response to α-PD-1/PD-L1 [199].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [199]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Self-citationHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationRittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718
Self-citationImmune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,782
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Self-citationNovello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Self-citationRizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415
Self-citation
Cited by
Sorted by citations
Items 401–500 of 570
Li, L., Xu, C., Wang, W., & Zhang, Q. (2024) · The Clinical Respiratory Journal · doi:10.1111/crj.13763 · Cited by 5
ATLANTIC: a sea change in immunotherapy for oncogene-driven lung cancer?
Lin, J. J., & Gainor, J. F. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30160-8 · Cited by 5
Pacheco, J. M., & Camidge, D. R. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30112-2 · Cited by 5
Lai, L., Zhan, Z., Feng, M., Li, F., Lai, L.-F., & Lu-xing, Z. (2020) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000921 · Cited by 5
Yang, Y., Pang, P., Xie, Z., Wang, N., Liang, H., & Zhao, L. (2020) · Translational Cancer Research · doi:10.21037/tcr.2020.03.82 · Cited by 5
Leone, G., Passiglia, F., Bironzo, P., Bertaglia, V., & Novello, S. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-710 · Cited by 4
Self-citationHu, R., Zhao, Z., Shi, Y., Shi, M., Xia, G., Yu, S., & Feng, J. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-20-3520 · Cited by 5
Zhou, F., & Zhou, C. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.011 · Cited by 5
Baglivo, S., Mandarano, M., Bellezza, G., Minotti, V., Bonaiti, A., Fischer, M. J., Birocchi, I., Roila, F., Metelli, N., Ludovini, V., et al. (2022) · Oncology and Therapy · doi:10.1007/s40487-022-00183-7 · Cited by 5
Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management
Safa, H., Rous, F. A., Belani, N., Borghaei, H., Gadgeel, S. M., & Halmos, B. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00937-3 · Cited by 6
First-line immunotherapy in non-small cell lung cancer: how to select and where to go
Mogavero, A., Cantale, O., Mollica, V., Anpalakhan, S., Addeo, A., Mountzios, G., Friedlaender, A., Kanesvaran, R., Novello, S., & Banna, G. L. (2023) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2024.2302356 · Cited by 5
Self-citationMorgensztern, D., & Govindan, R. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.034 · Cited by 5
Kemper, M., Elges, S., Kies, P., Wiebe, K., Lenz, G., Bleckmann, A., & Evers, G. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-359 · Cited by 4
Fujisaki, T., Miyauchi, E., Kida, G., Miura, Y., Watanabe, K., Ashinuma, H., Tamiya, M., Kikuchi, H., Arai, D., Takahashi, S., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108597 · Cited by 4
Self-citationMonnickendam, G. (2024) · Value in Health · doi:10.1016/j.jval.2024.02.008 · Cited by 4
Kholod, O., Baskett, W. I., Liu, D., Mitchem, J. B., Kaifi, J. T., Dooley, L. M., & Shyu, C. (2022) · Cancers · doi:10.3390/cancers14194759 · Cited by 4
Targeted Therapies in Early-Stage Resectable Non–Small-Cell Lung Cancer: New Kids on the Block
Liu, J., Amini, A., Govindarajan, A., Abuali, T., Mambetsariev, I., Massarelli, E., Villaflor, V. M., Villalona-Calero, M. A., West, H., Williams, T. M., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00445 · Cited by 4
He, Z., Duval, V., Jauslin, P. M., Gonçalves, A., Abegesah, A., Fan, C., Lim, K., Song, X., Chen, C. C.-K., Shi, X., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3063 · Cited by 4
Zhang, X., Zhang, H., Hou, F., Fang, T., Zhang, C., Wang, H., Song, S., Lan, H., Wang, Y., & Hou, H. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03434-1 · Cited by 4
Immune Checkpoints and Their Inhibition in T-Cell Lymphomas
Seňavová, J., Rajmonová, A., Heřman, V., Jura, F., Velasova, A., Hamová, I., Tkachenko, A. S., Kupcová, K., & Havránek, O. (2024) · Folia Biologica · doi:10.14712/fb2024070030123 · Cited by 4
Chen, Z., Gong, J., Chen, J. W., Yang, L., Hu, S., Chen, L., & Lu, H. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2488109 · Cited by 4
A pharmacovigilance analysis of post-marketing safety of durvalumab
Tan, A.-J., Liu, W., Lu, J., Tan, Q.-Y., Yu, Y., & Mo, D. (2025) · Scientific Reports · doi:10.1038/s41598-025-01583-1 · Cited by 4
Morgensztern, D., Cobo, M., Ponce-Aix, S., Postmus, P. E., Bennouna, J., Fischer, J. R., Juan, Ó., Stewart, D. J., Ardizzoni, A., Bhore, R., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.569715 · Cited by 4
Self-citationWang, L., Liu, F., Li, J., Ma, L., Feng, H., Liu, Q., Cho, W. C. S., Chen, H., Chen, H., Guo, H., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11090914 · Cited by 4
Radiopharmaceuticals as Novel Immune System Tracers
Ridge, N. A., Rajkumar-Calkins, A., Dudzinski, S. O., Kirschner, A. N., & Newman, N. B. (2022) · Advances in Radiation Oncology · doi:10.1016/j.adro.2022.100936 · Cited by 4
The safety profile of EGFR/ALK-TKIs administered immediately before or after ICIs in advanced NSCLC
Liao, D., Yu, L., Chen, S., Liu, G., Tang, J., & Yang, N. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109787 · Cited by 5
It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC
Akao, K., Oya, Y., Sato, T., Ikeda, A., Horiguchi, T., Gotô, Y., Hashimoto, N., Kondo, M., & Imaizumi, K. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00251 · Cited by 6
Song, P., Zhang, J., & Zhang, L. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s203192 · Cited by 4
Uenami, T., Ishijima, M., Kanazu, M., Kurebe, H., Edahiro, R., Nishida, K., Akazawa, Y., Yano, Y., Yamaguchi, T., & Mori, M. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.10.24 · Cited by 3
PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
Addeo, A., & Banna, G. L. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.07.09 · Cited by 4
The role of immunotherapy in fusion-driven lung cancer
Tan, A. C., Chan, J., & Khasraw, M. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1899816 · Cited by 4
Immune Checkpoint Inhibitor-Induced Insidiously Progressive, Fatal Interstitial Lung Disease
Kanaji, N., Watanabe, N., Inoue, T., Mizoguchi, H., Komori, Y., Ohara, Y., & Kadowaki, N. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15030115 · Cited by 3
Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context
Gullapalli, S., Remón, J., Hendriks, L. E. L., & Lopes, G. D. L., Jr. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s259308 · Cited by 3
Emerging strategies for biomaterial-assisted cancer immunotherapy
Joo, K. I. (2022) · Korean Journal of Chemical Engineering · doi:10.1007/s11814-021-0985-z · Cited by 3
Role of immunotherapy in metastatic EGFRm NSCLC
Dhabhar, B. N., Sahoo, T. P., & Akshay, J. K. (2022) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_49_21 · Cited by 3
Zhang, S., Liao, X., & Chen, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.978327 · Cited by 3
Iraqi, M., Bolel, P., Sarkar, R., Bhattacharya, B., Ahmad, M. A., Edri, A., Roisman, L. C., Elkabets, M., Shalata, W., Peled, N., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214054 · Cited by 3
Benz, S., Sherman, K., Dasanu, C. A., & Argote, J. A. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231184178 · Cited by 3
Wan, C., Zhang, Y., Liu, P., Mei, X., Cheng, G., Pang, J., Chen, S., Xu, J., Malhotra, J. D., Qian, H., et al. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-23-1399 · Cited by 3
Sun, Y., Dang, Q., Ge, Y., Zhang, J., Cheng, Q., Sun, H., Wang, L., Gao, A., Sun, Y., & Li, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e31863 · Cited by 3
Guo, L., Ji, Y., Guo, W., Song, P., Xue, X., Bai, G., Qiu, B., Ying, J., & Gao, S. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001642 · Cited by 3
Liu, Q., Wei, J.-G., Chen, Y., & Wang, J. (2022) · Medicine · doi:10.1097/md.0000000000030099 · Cited by 3
Self-citationSong, Q., Li, J., Xiong, Q., Long, Y., Yang, B. Y., Dong, Z. H., Liang, C. Y., & Yang, B. Y. (2023) · Immunotherapy · doi:10.2217/imt-2022-0302 · Cited by 3
Harmonization of Molecular Testing for Non-Small Cell Lung Cancer: Emphasis on PD-L1
Имянитов, Е. Н., Ivantsov, A. O., & Tsimafeyeu, I. V. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.549198 · Cited by 3
Li, D., Cheng, C., Song, W., Ni, P., Zhang, W., & Wu, X. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i36.11419 · Cited by 3
Ji, X., Jiang, R., Liu, T., Provencio, M., Lee, S. C., Zhan, Q., & Zhou, X. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-477 · Cited by 2
Immune and Genomic Heterogeneity of MET-Altered Non–Small Cell Lung Cancer
Liu, M., Minne, R. L., Javeri, S., Johnson, D. B., Tomlins, S. A., Kimple, R. J., & Baschnagel, A. M. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00048 · Cited by 2
Hu, S., Shi, X., Hu, Q., Wang, X., & Zhou, G. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189561 · Cited by 2
Wu, X., Shi, Y., Wang, D., Liu, B., Zhang, Y., Zhang, L., Qian, F., & Zhang, W. (2026) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2026.02.005 · Cited by 2
[Research Progress of Immunotherapy for Non-small Cell Lung Cancer with Drive Gene Mutation].
Deng, R., Zeng, Y., Pan, Y., Hu, C., & Wu, F. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.102.06 · Cited by 2
Mohanty, S. K., Mishra, S. K., Amin, M. B., Agaimy, A., & Fuchs, F. S. (2023) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000395 · Cited by 3
Fu, C., Liu, Z., An, T., Li, H., Hu, X., Li, X., Liu, X., Wu, D., Zhang, R., Li, K., et al. (2023) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2023.130439 · Cited by 2
Fujita, T., Amano, H., Nakamura, M., Hirano, S., & Nakamura, S. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.05.025 · Cited by 2
[Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer].
Liu, Y., & Miao, J. (2024) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.106.26 · Cited by 2
Whether specific genetic feature predicted immunotherapy efficacy: A case report
Chen, J., Pang, L., He, L., Li, T., & Cheng, X. (2024) · Medicine · doi:10.1097/md.0000000000036922 · Cited by 2
Leng, X., Mei, J., & Liu, L. (2018) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2018.11.10 · Cited by 2
Hochmair, M. J., Weinlinger, C., & Prosch, H. (2020) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000876 · Cited by 2
Approach to Anaplastic Lymphoma Kinase (ALK) Gene Rearranged Non–Small Cell Lung Cancer (NSCLC)
Gadgeel, S. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55433-6.00008-0 · Cited by 2
Bai, R., Chen, N., & Cui, J. (2018) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2018.08.11 · Cited by 2
Chen, J., Jiang, D., & Huang, F. (2019) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2019.04.06 · Cited by 2
Schabath, M. B., Dalvi, T. B., Dai, H. A., Crim, A., Midha, A., Shire, N. J., Gimbrone, N. T., Walker, J., Greenawalt, D. M., Lawrence, D., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s218635 · Cited by 2
Self-citationCons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
Metro, G., & Maïo, M. D. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.07.11 · Cited by 2
Rossi, S., Marinello, A., Pagliaro, A., Franceschini, D., Navarria, P., Finocchiaro, G., Toschi, L., Scorsetti, M., & Santoro, A. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2162044 · Cited by 3
Self-citationActivation of the complement system sensitizes immune checkpoint blockade
Shao, F., Yang, Y., Lu, Z., & He, J. (2022) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2022.11.005 · Cited by 2
Sharif, P. M., Khoshbin, A. P., Nasrollahzadeh, E., Keshavarz‐Fathi, M., & Rezaei, N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818006-8.00003-7 · Cited by 3
Chen, L., Liu, D., Zhang, Y., Jia, Y., Zhao, X., Liu, M., & Kong, T. (2023) · Immunotherapy · doi:10.2217/imt-2022-0315 · Cited by 2
Liu, Y., Miao, L., Chen, X., Zhu, X., Li, Y., He, J., Chen, P., Dai, S., Liu, Z., Ma, K., et al. (2024) · Medicine · doi:10.1097/md.0000000000038459 · Cited by 3
Cadranel, J. L., Fallet, V., Baldacci, S., & Cortot, A. B. (2020) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(20)30100-2 · Cited by 2
Breast Cancer Immunotherapy: From Biology to Current Clinical Applications
Leal, J. H. S., & McArthur, H. L. (2020) · European Medical Journal · doi:10.33590/emjoncol/19-00193 · Cited by 2
Verma, D., Faiz, S. A., Shannon, V. R., Altan, M., & Sheshadri, A. (2022) · Springer eBooks · doi:10.1007/978-3-031-00241-0_14 · Cited by 2
Liu, S. M., & Wu, Y.-L. L. C. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.02.020 · Cited by 2
FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression
Abdayem, P., & Planchard, D. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-628 · Cited by 1
Lan, M., Wang, T., Luo, D., Chen, Y., Liang, W., Kong, R., & Xie, Q. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1472545 · Cited by 1
Self-citationWang, F., Wei, X., Yang, M., Lu, C., Yang, X., Deng, J., Chen, Z., & Zhou, Q. H. (2025) · Thoracic Cancer · doi:10.1111/1759-7714.70025 · Cited by 1
Xu, M. (2025) · International Journal of Clinical and Experimental Pathology · doi:10.62347/bnvx1803 · Cited by 1
Cao, W., Kou, F., Hu, W., Hu, L., Nie, J., Dai, L., Zhang, J., Rui, J., Knetki‐Wróblewska, M., Antonoff, M. B., et al. (2025) · Translational Lung Cancer Research · doi:10.21037/tlcr-2025-716 · Cited by 1
Cho, B. C., Ahn, M., Nishio, M., Murakami, H., Wan-Kim, D., Kim, S., Karam, S. D., Estival, A., Lin, C.-C., Trigo, J. M., et al. (2025) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2025.100884 · Cited by 1
Self-citationHe, J., Liu, C., Ma, F., Zhou, Y., & Liu, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1622573 · Cited by 1
Komninos, D., Psarros, E., Theochari, E., Tsirikos, G., Sampsonas, F., & Tzouvelekis, A. (2026) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2026.2631816 · Cited by 1
Ito, A., Kang, S. W., Jang, H.-J., Shim, J. S., Lee, C., Ranchod, P., Lee, G., Mitra, S., Jeon, J., Syarif, A. H., et al. (2026) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2026.02.030 · Cited by 1
Mutant-Selective T-cell Receptor Therapy for Solid Tumors
Parry, S. R., Jang, C., Leal, A., & Punekar, S. R. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0894 · Cited by 1
Zhang, C., Jiang, B., Yan, L.-X., Peng, L., Li, J.-H., Chen, Z.-Y., Sun, Y.-X., su, J., Liao, R.-Q., Dong, S., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103994 · Cited by 1
Niu, J., Jing, W., Liu, Z., Si, Y., & 刘寨东 (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1845547 · Cited by 1
Li, Y., Zhang, L., & Chen, J. (2020) · PubMed · doi:10.11817/j.issn.1672-7347.2020.190054 · Cited by 1
PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
Addeo, A., & Banna, G. L. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.07.10 · Cited by 1
Wu, S., Chiang, C., Wang, C., Hung, J., Hsia, T., Kuo, C. S., & Shih, J. (2022) · Journal of Cancer · doi:10.7150/jca.74617 · Cited by 1
Self-citationCombination regimens in EGFR-mutated lung cancer: can we get ORIENT-ed?
Elkrief, A., & Yu, H. A. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00449-1 · Cited by 1
[Advances in ICIs Therapy after TKIs Resistance in Patients with EGFR Mutant NSCLC: A Review].
Chen, R., Jiang, C., Ma, L., & Zhang, S. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.101.37 · Cited by 1
Peng, Z., & Xu, Y. (2022) · Current Problems in Cancer Case Reports · doi:10.1016/j.cpccr.2022.100199 · Cited by 1
Matsumura, S., Ano, S., Kikuchi, N., Masuda, M., Osawa, H., Kondo, Y., Ishii, Y., & Hizawa, N. (2023) · SAGE Open Medical Case Reports · doi:10.1177/2050313x231159504 · Cited by 1
Durvalumab supplementation for non-small-cell lung cancer: a meta-analysis study
Wang, C., Fu, H., & Wang, F. (2024) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-024-02940-3 · Cited by 1
Ren, J., Wang, K., Meng, Q., Xu, C., Liu, C., Wang, Y., & Wang, G. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241308389 · Cited by 1
Xiao, Y., Wang, H., Lu, J., Pang, J., Liu, S., Zhou, Y., Shi, X., & Liang, Z. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-682 · Cited by 1
Immunotherapy rechallenge after significant toxicity - can it be done successfully?
Tan, A., McSweeney, T., Sikotra, N., Adler, B. D., van Hagen, T., Summers, Q. A., Dean, A. P., Hagen, N., DeMarie, A., Gabbay, E., et al. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2452838 · Cited by 1
Zhang, S., Liu, J., Liu, J., & Lu, K. (2025) · Medicine · doi:10.1097/md.0000000000044144 · Cited by 1
The role of immunotherapy in the treatment of non-small cell lung cancer
Kadlec, B. (2018) · Onkologie · doi:10.36290/xon.2018.034 · Cited by 1
Current and future developments of immunotherapy in lung cancer
Mauti, L. A., Finazzi, T., Früh, M., Pless, M., Zippelius, A., & Rothschild, S. I. (2018) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-018-0411-3 · Cited by 1
[Hypotension During Pembrolizumab Infusion: Case Report and Literature Review].
Song, P., Zhang, X., & Zhang, L. (2019) · PubMed Central · doi:10.3779/j.issn.1009-3419.2019.11.09 · Cited by 1
Progress in the Study on PD-L1 Inhibitor in the Treatment of EGFR-Mutant Non-Small Cell Lung Cancer
Wang, Y., Wang, F., Zhang, F., Niu, L., Shen, L., Zhu, L., Kang, M., Xie, X., Wang, Y., & Gao, Y. (2020) · Clinical Oncology and Research · doi:10.31487/j.cor.2020.02.08 · Cited by 1
Durvalumab for the treatment of PD-L1 non-small cell lung cancer
Naito, T., Shiraishi, H., & Fujiwara, Y. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1855075 · Cited by 1
Metadata
- Authors
- Garassino, M. C., Cho, B.-C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J. E., Powderly, J., Chouaid, C., Bidoli, P., Wheatley-Price, P., Park, K., Soo, R. A., Huang, Y., Wadsworth, C., Dennis, P. A., Rizvi, N. A., Paz-Ares Rodriguez, L., Novello, S., Hiret, S., Schmid, P., Laack, E., Califano, R., Maemondo, M., Kim, S.-W., Chaft, J., Vicente Baz, D., Berghmans, T., Kim, D.-W., Surmont, V., Reck, M., Han, J.-Y., Holgado Martin, E., Belda Iniesta, C., Oe, Y., Chella, A., Chopra, A., Robinet, G., Soto Parra, H., Thomas, M., Cheema, P., Katakami, N., Su, W.-C., Kim, Y.-C., Wolf, J., Lee, J.-S., Saka, H., Milella, M., Ramos Garcia, I., Sibille, A., Yokoi, T., Kang, E. J., Atagi, S., Spaeth-Schwalbe, E., Nishio, M., Imamura, F., Gabrail, N., Veillon, R., Derijcke, S., Maeda, T., Zylla, D., Kubiak, K., Santoro, A., Uy, M. N., Lucien Geater, S., Italiano, A., Kowalski, D., Barlesi, F., Chen, Y.-M., Spigel, D., Chewaskulyong, B., Garcia Gomez, R., Alvarez Alvarez, R., Yang, C.-H., Hsia, T.-C., Denis, F., Sakai, H., Vincent, M., Goto, K., Bosch-Barrera, J., Weiss, G., Canon, J.-L., Scholz, C., Aglietta, M., Kemmotsu, H., Azuma, K., Bradbury, P., Feld, R., Chachoua, A., Jassem, J., Juergens, R., Palmero Sanchez, R., Malcolm, A., Vrindavanam, N., Kubota, K., Waller, C., Waterhouse, D., Coudert, B., Mark, Z., Satouchi, M., Chang, G.-C., Herzmann, C., Chaudhry, A., Giridharan, S., Hesketh, P., Ikeda, N., Boccia, R., Iannotti, N., Haigentz, M., Reynolds, J., Querol, J., Nakagawa, K., Sugawara, S., Tan, E. H., Hirashima, T., Gettinger, S., Kato, T., Takeda, K., Juan Vidal, O., Mohn-Staudner, A., Panwalkar, A., Daniel, D., Kobayashi, K., Ladrera, G. E. I., Schulte, C., Sebastian, M., Cernovska, M., Coupkova, H., Havel, L., Pauk, N., Singh, J., Murakami, S., Csoszi, T., Losonczy, G., Price, A., Anderson, I., Iqbal, M., Torri, V., Juhasz, E., Khanani, S., Koubkova, L., Levy, B., Page, R., Bocskei, C., Crinò, L., Einspahr, D., Hagenstad, C., Juat, N., Overton, L., Garrison, M., & Szalai, Z.
- Affiliations
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Yonsei University (KR)
- CHA University Bundang Medical Center (KR)
- Université Toulouse III - Paul Sabatier (FR)
- KU Leuven (BE)
- Moffitt Cancer Center (US)
- Carolina BioOncology Institute (US)
- Inserm (FR)
- Azienda Ospedaliera San Gerardo (IT)
- Samsung Medical Center (KR)
- National University Cancer Institute, Singapore (SG)
- AstraZeneca (United States) (US)
- AstraZeneca (United Kingdom) (GB)
- Columbia University Irving Medical Center (US)
- University of Turin (IT)
- Institut de Cancérologie de l'Ouest (FR)
- Imperial College London (GB)
- Université Libre de Bruxelles (BE)
- German Center for Lung Research (DE)
- University of Palermo (IT)
- Hospital Universitario Virgen del Rocío (ES)
- University of Ottawa (CA)
- Corresponding author
- Garassino, Marina Chiara
- ORCID
- Garassino, Marina Chiara
- Cho, Byoung-Chul
- Kim, Joo-Hang
- Mazières, Julien
- Vansteenkiste, Johan
- Powderly, John
- Chouaid, Christos
- Park, Keunchil
- Soo, Ross A
- Huang, Yifan
- Rizvi, Naiyer A
- Novello, Silvia
- Hiret, Sandrine
- Schmid, Peter
- Califano, Raffaele
- Maemondo, Makoto
- Kim, Sang-We
- Chaft, Jamie
- Berghmans, Thierry
- Kim, Dong-Wan
- Surmont, Veerle
- Reck, Martin
- Han, Ji-Youn
- Chella, Antonio
- Chopra, Akhil
- Cheema, Parneet
- Katakami, Nobuyuki
- Su, Wu-Chou
- Kim, Young-Chul
- Lee, Jong-Seok
- Saka, Hideo
- Milella, Michele
- Sibille, Anne
- Yokoi, Takashi
- Kang, Eun Joo
- Atagi, Shinji
- Nishio, Makoto
- Imamura, Fumio
- Gabrail, Nashat
- Derijcke, Sofie
- Zylla, Dylan
- Santoro, Armando
- Kowalski, Dariusz
- Chen, Yuh-Min
- Spigel, David
- Hsia, Te-Chun
- Denis, Fabrice
- Sakai, Hiroshi
- Vincent, Mark
- Weiss, Glen
- Canon, Jean-Luc
- Aglietta, Massimo
- Azuma, Koichi
- Chachoua, Abraham
- Jassem, Jacek
- Juergens, Rosalyn
- Kubota, Kaoru
- Waller, Cornelius
- Waterhouse, David
- Coudert, Bruno
- Satouchi, Miyako
- Chang, Gee-Chen
- Herzmann, Christian
- Giridharan, Selvaraj
- Hesketh, Paul
- Ikeda, Norihiko
- Haigentz, Missak
- Nakagawa, Kazuhiko
- Sugawara, Shunichi
- Gettinger, Scott
- Kato, Terufumi
- Daniel, Davey
- Kobayashi, Kunihiko
- Sebastian, Martin
- Havel, Libor
- Singh, Joginder
- Murakami, Shuji
- Levy, Benjamin
- Page, Ray
- Crinò, Lucio
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 19
- Issue
- 4
- Pages
- 521-536
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC7771363
- OpenAlex
- W2791290180
- Cited by
- 568
- References
- 29
- Citations by year
- 2026: 15 · 2025: 30 · 2024: 55 · 2023: 61 · 2022: 85 · 2021: 96 · 2020: 92 · 2019: 85 · 2018: 47
- FWCI
- 30.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- HAL (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- durvalumab, advanced non-small cell lung cancer, third-line therapy, PD-L1 expression, immune checkpoint inhibitors, EGFR mutation, ALK rearrangement, objective response rate, treatment safety, PD-L1 inhibitors, immune-related adverse events
- MeSH terms
- Antineoplastic Agents, Immunological, Injection Site Reaction, Anaplastic Lymphoma Kinase, Progression-Free Survival, Aged, Antibodies, Monoclonal, Aspartate Aminotransferases, Carcinoma, Non-Small-Cell Lung, Diarrhea, Fatigue, Female, gamma-Glutamyltransferase, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Pneumonia, 4-Butyrolactone, B7-H1 Antigen, Response Evaluation Criteria in Solid Tumors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
